Cargando…

Micropulse laser trabeculoplasty and reduction of intraocular pressure: A preliminary study

PURPOSE: The purpose of the study was to measure the change in intraocular pressure (IOP) after micropulse laser trabeculoplasty (MLT) and to evaluate subgroups based on initial IOP and severity of glaucoma. METHODS: This was a retrospective study of 34 eyes that were treated with MLT. Follow-up mea...

Descripción completa

Detalles Bibliográficos
Autores principales: Phan, Ryan, Bubel, Kevin, Fogel, Joshua, Brown, Aaron, Perry, Henry, Morcos, Marcelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8982934/
https://www.ncbi.nlm.nih.gov/pubmed/35391804
http://dx.doi.org/10.4103/1319-4534.337860
Descripción
Sumario:PURPOSE: The purpose of the study was to measure the change in intraocular pressure (IOP) after micropulse laser trabeculoplasty (MLT) and to evaluate subgroups based on initial IOP and severity of glaucoma. METHODS: This was a retrospective study of 34 eyes that were treated with MLT. Follow-up measurements were obtained at 3 months. Paired t-tests compared baseline to follow-up. RESULTS: IOP reduction approached significance (P = 0.055) for lower mean IOP from pre- to post-treatment. In the subset of those with baseline IOP >16, mean IOP was significantly lower (P = 0.001) from pretreatment (mean = 19.43, standard deviation [SD] = 2.48) to posttreatment (mean = 16.91, SD = 3.37). There were 34.8% (8/23) with a 20% reduction from baseline IOP. For patients with no glaucoma/early glaucoma, mean IOP was significantly lower (P = 0.003) from pretreatment (mean = 19.62, SD = 3.36) to posttreatment (mean = 16.62, SD = 3.01). In the subset of those with moderate/advanced glaucoma, there were no significant changes for mean IOP from pretreatment to posttreatment. CONCLUSION: Patients with higher initial IOP and in the early stages of glaucoma were more likely to benefit from MLT in lowering IOP. A randomized clinical trial is necessary to confirm these preliminary findings. We recommend that clinicians should consider MLT in the management of early glaucoma and among those with IOP >16 mmHg.